Coenzyme Q10 is a vitamin-like compound, found in abundant levels in the mitochondria of cells as it is a substance vital to energy production. Svend Aage Mortensen, from Copenhagen University Hospital (Denmark), and colleagues administered oral Coenzyme Q10 (100 mg, three times a day), or placebo, to 420 European and Asian subjects and followed them for a two-year period. At the end of the study term, 25% of the patients in the placebo group experienced a major adverse cardiovascular events, as compared to 14% in the group receiving CoQ10. Further, mortality and hospitalizations were lower in the supplemented group: 18 patients died in the CoQ10 group, as compared to 36 in the placebo group. The researchers observed that CoQ10 reduce the levels ofNT-proBNP, a heart failure biomarker.
CoQ10 Reduces Heart Failure Deaths
Mortensen SA, Kumar A, Dolliner P, et al. “The effect of Coenzyme Q10 on morbidity and mortality in chronic heart failure. Results from the Q-SYMBIO study” [Abstract #440]. Presented at 2013 Congress of the Heart Failure Association of the European Society of Cardiology, 29 May 2013.
RELATED ARTICLES